Article: DOR BioPharma licenses irritable bowel syndrome patents.(Brief Article)

DOR BioPharma, Inc. (Lake Forest, IL) executed an exclusive option with the University of Texas Medical Branch at Galveston (UTMB) (Galveston, TX) to license patent applications covering the use of oral luminally active anti-inflammatory drugs, such as orBec (oral beclomethasone diproprionate), for the treatment of irritable bowel syndrome.

Dr. Jay Pasricha, Director of the Gastroenterology and Hepatology Division at UTMB stated, "The role that subtle gastrointestinal inflammation plays in irritable bowel syndrome is only beginning to be appreciated. Recent evidence suggests that many cases of irritable bowel syndrome may be driven by the persistence of ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!